Close Menu

UBS

The Seattle-based genomics technology firm said it intends to use the funds for working capital and general corporate purposes.

The company expects product and service revenue totaling $30.1 million, driven by higher instrument revenue, offset by declining consumables revenue.

The investment firm said that Grail's revenue trajectory is uncertain, and given the firm's operating loss, it will significantly dilute Illumina's earnings.

Only 5 percent of respondents said they got tested through a consumer genomics firm, but the future market could be worth as much as $7 billion, analysts at UBS estimated.

A Cepheid executive today provided investors with an update on the company's molecular diagnostic pipeline, stating that the firm currently has 14 tests in development for its automated GeneXpert platform and that it expects to offer the broadest test menu of any molecular diagno

Several mass spec vendors presented this week at the UBS Global Life Sciences Conference in New York City, offering information on various aspects of their businesses, including portions of their proteomics portfolios.

NEW YORK (GenomeWeb News) – The UBS Global Life Sciences Conference concluded on Wednesday with presentations in the afternoon by GenturaDx and Epigenomics.

Speaking at the UBS Global Life Sciences conference in New York on Monday, Bio-Rad Laboratories President and CEO Norman Schwartz told attendees that Bio-Rad planned to launch the platform to test for sexually transmitted diseases.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.